In the last three months, 13 Wall Street analysts have shared their 12-month price targets for BioNTech SE, with expectations ranging from a low of $85 to a high of $171. The consensus, however, lands at an average price target of $107.36, reflecting mixed views on the company's post-COVID diversification efforts and future revenue streams.
McCormick & Co (NYSE: MKC) has a consensus price target of $77.50 based on ratings from 16 analysts. Price predictions range from $94 on the high end, provided by Exane BNP Paribas, to a more conservative $57 on the low end, forecast by JP Morgan as of January 2024.
Thirteen top analysts have weighed in on Aflac’s stock, setting their 12-month price targets. The average forecast sits at $91.77, with estimates ranging from a low of $75 to a high of $109. If the analysts are right, the average target suggests a potential drop of 15.86% from the current stock price of $109.07.
According to 16 Wall Street analysts who’ve weighed in over the past three months, Cintas has a 12-month average price target of $769.00. The projections range from a high of $875.00 to a low of $590.00. With Cintas currently trading at $799.59, that average target suggests a potential downside of -3.83%..
In the grand scheme of economic shifts, the story of currency debasement is as old as money itself.
The consensus target? It's pegged at $211.46. But hold onto your hats—some are shooting for the stars with predictions as high as $310.00. On the flip side, there are the naysayers, the ones who see things tumbling down to $85.00. Now, that's a range to reckon with!
Based on 15 Wall Street analysts offering 12 month price targets for Northrop Grumman in the last 3 months. The average price target is $529.31 with a high forecast of $605.00 and a low forecast of $477.00. The average price target represents a 7.42% change from the last price of $492.73.
In the past three months, nine Wall Street analysts have provided 12-month price targets for Raytheon Technologies ($RTX). The average price target stands at $118.56, with projections ranging from a high of $142.00 to a low of $91.00. This spread highlights varying perspectives on RTX's potential performance, reflecting both optimism about its growth prospects and caution about possible risks.
This Week’s a.i. Stock Spotlight is TG Therapeutics ($TGTX) TG Therapeutics, Inc. ($TGTX) is making significant strides in the biopharmaceutical industry with a focused mission to develop and commercialize novel ...
This Week’s a.i. Stock Spotlight is Costco ($COST) Costco Wholesale Corporation distinguishes itself in the retail landscape through a unique business model that emphasizes bulk sales and membership exclusivity, contrasting ...